In the study, researchers used data from more than 227,000 people in Sweden's patient data registry, a national database of health records. The study's subjects were diagnosed with alcohol use ...

So far, prasinezumab has yet to notch a clear victory in clinical testing. A trial titled “PASADENA” enrolled a little over 300 participants with early Parkinson’s and compared two different doses of ...

Besides, newer drug regimens and implementation studies are under evaluation for the potential ... was done following anti-TB treatment owing to the risk of cross-reactivity between rifampicin and ...

Researchers have used a new gold-based drug to slow tumor growth in animals by 82% and target cancers more selectively than standard chemotherapy drugs, according to a new study. A new gold-based ...

Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, causing the company’s shares to fall Thursday. Vertex, based in ...

Based on the above results and subject to regulatory discussions, Sanofi and Teva intend to start a late-stage study on the drug across both UC and CD indications. The companies also plan to ...

A highly anticipated obesity-drug candidate from biotech Amgen helped patients shed a significant amount of weight in a midstage study, but fell short of the loftier expectations of some investors.

Keros Therapeutics (NASDAQ:KROS) stock plunged 73% Thursday after the company said it has halted two arms of a Phase 2 clinical study of its drug cibotercept in patients with pulmonary arterial ...

A new gold-based drug can slow tumor growth in animals by 82% and target cancers more selectively than standard chemotherapy drugs, according to a study by Australian and Indian researchers.

Eli Lilly's Zepbound outperformed Novo Nordisk's top weight loss drug in a recent study. Both drugs showed that they were highly effective in helping people lose weight, but Zepbound's numbers ...